PMID- 19161454
OWN - NLM
STAT- MEDLINE
DCOM- 20090601
LR  - 20090123
IS  - 1365-2885 (Electronic)
IS  - 0140-7783 (Linking)
VI  - 32
IP  - 1
DP  - 2009 Feb
TI  - Analytical determination and pharmacokinetics of robenacoxib in the dog.
PG  - 41-8
LID - 10.1111/j.1365-2885.2008.01035.x [doi]
AB  - An analytical method was developed and validated for the measurement of the novel 
      analgesic and anti-inflammatory drug robenacoxib in blood and plasma of dogs and 
      cats. To prevent nonreproducible carry-over effects, an initial solid phase 
      extraction procedure was followed by high pressure liquid chromatography analysis 
      for samples with concentrations in the range 500 to 20,000 ng/mL. To improve 
      accuracy, samples of concentration 3 to 100 ng/mL were analyzed by liquid 
      chromatography-mass spectrometry. Applying these methods, blood 
      concentration-time profiles and pharmacokinetic variables of robenacoxib in dogs 
      were determined in a four-phase cross-over study, which compared different routes 
      of administration of the drug, including intravenous (i.v.) injection, oral 
      application with and without feed, and subcutaneous (s.c.) application. After 
      i.v. administration the mean clearance from blood was 0.81 L/kg/h, the volume of 
      distribution was 0.77 L/kg for the elimination phase and 0.24 L/kg for 
      steady-state, and the terminal half-life in blood was 0.63 h. Maximum blood 
      concentrations were obtained in less than 1 h following oral or s.c. application. 
      Absolute bioavailability was 88% after s.c. injection, 84% after oral 
      administration to fasted dogs, but was reduced to 62% when applied orally to fed 
      dogs. In canine and feline plasma the degree of binding of robenacoxib to plasma 
      protein in vitro was greater than 98%. The blood:plasma concentration ratio was 
      0.44:1 in the dog and 0.65:1 in the cat. In conclusion analytical methods for the 
      quantification of robenacoxib in blood and plasma in the dog and cat were 
      developed and validated. In dogs, robenacoxib has good bioavailability after oral 
      (84%) and subcutaneous (88%) administration.
FAU - Jung, M
AU  - Jung M
AD  - Novartis Animal Health Research Centre, St-Aubin, Switzerland.
FAU - Lees, P
AU  - Lees P
FAU - Seewald, W
AU  - Seewald W
FAU - King, J N
AU  - King JN
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Vet Pharmacol Ther
JT  - Journal of veterinary pharmacology and therapeutics
JID - 7910920
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Cyclooxygenase 2 Inhibitors)
SB  - IM
MH  - Administration, Oral
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & 
      dosage/blood/*pharmacokinetics
MH  - Area Under Curve
MH  - Biological Availability
MH  - Chromatography, High Pressure Liquid/standards/*veterinary
MH  - Chromatography, Liquid
MH  - Cross-Over Studies
MH  - Cyclooxygenase 2 Inhibitors/administration & dosage/blood/*pharmacokinetics
MH  - Dogs/blood/*metabolism
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Half-Life
MH  - Injections, Intravenous/veterinary
MH  - Injections, Subcutaneous/veterinary
MH  - Intestinal Absorption/drug effects
MH  - Male
MH  - Metabolic Clearance Rate
MH  - Random Allocation
MH  - Sensitivity and Specificity
EDAT- 2009/01/24 09:00
MHDA- 2009/06/02 09:00
CRDT- 2009/01/24 09:00
PHST- 2009/01/24 09:00 [entrez]
PHST- 2009/01/24 09:00 [pubmed]
PHST- 2009/06/02 09:00 [medline]
AID - JVP1035 [pii]
AID - 10.1111/j.1365-2885.2008.01035.x [doi]
PST - ppublish
SO  - J Vet Pharmacol Ther. 2009 Feb;32(1):41-8. doi: 10.1111/j.1365-2885.2008.01035.x.